CD19 and cancer: Amongst the four approved CD19-CAR-T cell products, data to support the choice of the optimal therapy for different B-lineage-derived cancers are lacking, and further evaluation in clinical trials will be required to identify a treatment algorithm that enables timely and optimal use of these CAR T cell treatments [26].